A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B

A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B

In chronic Hepatitis B Virus (HBV) infections HBV-specific T cells are functionally impaired. Immunotherapy may restore HBV-specific T cell responses essential for sustained disease remission off-treatment and induction of a functional cure. Chimigen® Molecules are fusion proteins of antigen(s) with...

Full description

Bibliographic Details
Main Authors: Allan Ma, Bruce Motyka, Klaus Gutfreund, Yuenian Eric Shi, Rajan George
Format: Article
Language:English
Published: Taylor & Francis Group 2020-04-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
hepatitis b virus
chronic hepatitis b
dendritic cells
immunotherapy
fusion protein
Online Access:http://dx.doi.org/10.1080/21645515.2019.1689080

Similar Items

Similar Items